Gene-Editing Start-Up Poseida Lands $30.5M to Advance CAR T – hcanews.com
|
Gene-Editing Start-Up Poseida Lands $30.5M to Advance CAR T
hcanews.com Read: Fighting Cancer with CAR T and Big Data The first CAR T therapies gained FDA approval last year. Kymriah, a fruit of Novartis's efforts, first got the green light in August, followed by Kite Pharma's Yescarta. CAR T, of course, involves the … |
